Price Graph
Price
Yield
These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
Washington
|
|
91-1663741
|
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification Number)
|
|
|
|
|
|
201 Elliott Avenue West
Seattle, Washington
|
|
98119
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
Large accelerated filer
|
|
¨
|
|
Accelerated filer
|
|
x
|
|
Non-accelerated filer
|
|
¨
(Do not check if a smaller reporting company)
|
|
Smaller reporting company
|
|
¨
|
|
•
|
our plans for sales, marketing and distribution of OMIDRIA
®
(phenylephrine and ketorolac injection) 1%/0.3%;
|
|
•
|
our expectations regarding our product sales and our estimate regarding how long our existing cash, cash equivalents, short-term investments and revenues will be sufficient to fund our anticipated operating expenses, capital expenditures and interest and principal payments on our outstanding notes under our Loan and Security Agreement, or the Oxford/EWB Loan Agreement, with Oxford Finance LLC, or Oxford, and East West Bank, or EWB;
|
|
•
|
our ability to raise additional capital through the capital markets, including under our at-the-market equity facility with JonesTrading Institutional Services LLC, or JonesTrading, or through one or more corporate partnerships, equity offerings, debt financings, collaborations, licensing arrangements or asset sales;
|
|
•
|
our ability to forecast accurately wholesaler demand as well as our estimates of chargebacks and rebates, distribution fees and estimated product returns;
|
|
•
|
our ability to enter into acceptable arrangements with potential corporate partners, including with respect to OMIDRIA;
|
|
•
|
our expectations regarding the clinical, therapeutic and competitive benefits of OMIDRIA and our product candidates;
|
|
•
|
our anticipation that we will rely on contract manufacturers to manufacture OMIDRIA for commercial sale and to manufacture our product candidates and our expectations regarding product supply and manufacturing of OMIDRIA;
|
|
•
|
our expectations about the commercial competition that OMIDRIA and our product candidates, if commercialized, may face;
|
|
•
|
our expectation that the OMIDRIAssure™ Reimbursement Services Program will increase patient access to OMIDRIA;
|
|
•
|
the extent of protection that our patents provide and that our pending patent applications will provide, if patents issue from such applications, for our technologies, programs, products and product candidates;
|
|
•
|
when or whether the dosing limitations in our OMS824 program may be removed;
|
|
•
|
our ability to design and successfully complete clinical trials and other studies for our products and product candidates and our plans and expectations regarding our clinical trials, including our clinical trials for OMS721 and for OMS824;
|
|
•
|
the expected course and costs of existing claims, legal proceedings and administrative actions, our involvement in potential claims, legal proceedings and administrative actions, and the potential outcomes and effects of both existing and potential claims, legal proceedings and administrative actions, as well as regulatory determinations, on our business, prospects, financial condition and results of operations;
|
|
•
|
our expectations regarding our OMS103 exclusive license agreement including, without limitation, the manufacturing and commercialization of OMS103 and the commencement and subsequent continuation of product sales on which we could receive royalty revenue; and
|
|
•
|
our expected financial position, performance, revenues, growth, expenses, magnitude of net losses and the availability of resources.
|
|
|
Page
|
|
|
March 31,
2016 |
|
December 31,
2015 |
||||
|
Assets
|
|
|
|
||||
|
Current assets:
|
|
|
|
||||
|
Cash and cash equivalents
|
$
|
978
|
|
|
$
|
1,365
|
|
|
Short-term investments
|
12,266
|
|
|
26,898
|
|
||
|
Receivables
|
6,646
|
|
|
6,517
|
|
||
|
Inventory
|
1,972
|
|
|
472
|
|
||
|
Prepaid expense
|
2,460
|
|
|
1,894
|
|
||
|
Total current assets
|
24,322
|
|
|
37,146
|
|
||
|
Property and equipment, net
|
898
|
|
|
951
|
|
||
|
Restricted cash and investments
|
10,679
|
|
|
10,679
|
|
||
|
Other assets
|
73
|
|
|
219
|
|
||
|
Total assets
|
$
|
35,972
|
|
|
$
|
48,995
|
|
|
|
|
|
|
||||
|
Liabilities and shareholders’ deficit
|
|
|
|
||||
|
Current liabilities:
|
|
|
|
||||
|
Accounts payable
|
$
|
5,332
|
|
|
$
|
6,428
|
|
|
Accrued expenses
|
12,120
|
|
|
9,752
|
|
||
|
Current portion of notes payable
|
69
|
|
|
73
|
|
||
|
Total current liabilities
|
17,521
|
|
|
16,253
|
|
||
|
Notes payable, net
|
49,973
|
|
|
49,769
|
|
||
|
Deferred rent
|
9,220
|
|
|
9,207
|
|
||
|
Commitments and contingencies (Note 8)
|
|
|
|
||||
|
Shareholders’ deficit:
|
|
|
|
||||
|
Preferred stock, par value $0.01 per share, 20,000,000 authorized and none issued and outstanding at March 31, 2016 and December 31, 2015
|
—
|
|
|
—
|
|
||
|
Common stock, par value $0.01 per share, 150,000,000 authorized at March 31, 2016 and December 31, 2015; 39,119,154 and 38,040,891 issued and outstanding at March 31, 2016 and December 31, 2015, respectively
|
391
|
|
|
380
|
|
||
|
Additional paid-in capital
|
382,548
|
|
|
376,528
|
|
||
|
Accumulated deficit
|
(423,681
|
)
|
|
(403,142
|
)
|
||
|
Total shareholders’ deficit
|
(40,742
|
)
|
|
(26,234
|
)
|
||
|
Total liabilities and shareholders’ deficit
|
$
|
35,972
|
|
|
$
|
48,995
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2016
|
|
2015
|
||||
|
Revenues
|
|
|
|
||||
|
Product sales, net
|
$
|
7,246
|
|
|
$
|
238
|
|
|
Grant revenue
|
173
|
|
|
150
|
|
||
|
Total revenue
|
7,419
|
|
|
388
|
|
||
|
|
|
|
|
||||
|
Costs and expenses
|
|
|
|
||||
|
Cost of product sales
|
327
|
|
|
11
|
|
||
|
Research and development
|
15,434
|
|
|
9,318
|
|
||
|
Selling, general and administrative
|
11,110
|
|
|
8,989
|
|
||
|
Total costs and expenses
|
26,871
|
|
|
18,318
|
|
||
|
Loss from operations
|
(19,452
|
)
|
|
(17,930
|
)
|
||
|
Interest expense
|
(1,375
|
)
|
|
(957
|
)
|
||
|
Other income (expense), net
|
288
|
|
|
218
|
|
||
|
Net loss
|
$
|
(20,539
|
)
|
|
$
|
(18,669
|
)
|
|
Comprehensive loss
|
$
|
(20,539
|
)
|
|
$
|
(18,669
|
)
|
|
Basic and diluted net loss per share
|
$
|
(0.54
|
)
|
|
$
|
(0.51
|
)
|
|
Weighted-average shares used to compute basic and diluted net loss per share
|
38,317,084
|
|
|
36,483,559
|
|
||
|
|
Three Months Ended
March 31, |
||||||
|
|
2016
|
|
2015
|
||||
|
Operating activities:
|
|
|
|
||||
|
Net loss
|
$
|
(20,539
|
)
|
|
$
|
(18,669
|
)
|
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
||||
|
Depreciation and amortization
|
53
|
|
|
55
|
|
||
|
Stock-based compensation expense
|
4,422
|
|
|
2,517
|
|
||
|
Non-cash interest expense
|
213
|
|
|
212
|
|
||
|
Changes in operating assets and liabilities:
|
|
|
|
||||
|
Receivables
|
(129
|
)
|
|
(146
|
)
|
||
|
Inventory
|
(1,500
|
)
|
|
—
|
|
||
|
Prepaid expenses and other noncurrent assets
|
(420
|
)
|
|
725
|
|
||
|
Accounts payable and accrued expenses
|
1,272
|
|
|
(2,170
|
)
|
||
|
Net cash used in operating activities
|
(16,628
|
)
|
|
(17,476
|
)
|
||
|
Investing activities:
|
|
|
|
||||
|
Purchases of investments
|
(18
|
)
|
|
(79,389
|
)
|
||
|
Proceeds from the sale and maturities of investments
|
14,650
|
|
|
17,300
|
|
||
|
Net cash provided by (used in) investing activities
|
14,632
|
|
|
(62,089
|
)
|
||
|
Financing activities:
|
|
|
|
||||
|
Proceeds from issuance of common stock and pre-funded warrants, net
|
—
|
|
|
79,076
|
|
||
|
Proceeds upon exercise of stock options and warrants
|
1,609
|
|
|
1,576
|
|
||
|
Net cash provided by financing activities
|
1,609
|
|
|
80,652
|
|
||
|
Net (decrease) increase in cash and cash equivalents
|
(387
|
)
|
|
1,087
|
|
||
|
Cash and cash equivalents at beginning of period
|
1,365
|
|
|
354
|
|
||
|
Cash and cash equivalents at end of period
|
$
|
978
|
|
|
$
|
1,441
|
|
|
Supplemental cash flow information
|
|
|
|
||||
|
Cash paid for interest
|
$
|
776
|
|
|
$
|
745
|
|
|
|
March 31,
|
||||
|
|
2016
|
|
2015
|
||
|
Outstanding options to purchase common stock
|
9,302,348
|
|
|
8,365,741
|
|
|
Warrants and pre-funded warrants to purchase common stock
|
—
|
|
|
1,160,788
|
|
|
Total
|
9,302,348
|
|
|
9,526,529
|
|
|
|
March 31, 2016
|
||||||||||||||
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||
|
|
(In thousands)
|
||||||||||||||
|
Assets:
|
|
|
|
|
|
|
|
||||||||
|
Money-market funds classified as non-current restricted cash and investments
|
$
|
10,679
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
10,679
|
|
|
Money-market funds classified as short-term investments
|
12,266
|
|
|
—
|
|
|
—
|
|
|
12,266
|
|
||||
|
Total
|
$
|
22,945
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
22,945
|
|
|
|
December 31, 2015
|
||||||||||||||
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||
|
|
(In thousands)
|
||||||||||||||
|
Assets:
|
|
|
|
|
|
|
|
||||||||
|
Money-market funds classified as non-current restricted cash and investments
|
$
|
10,679
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
10,679
|
|
|
Money-market funds classified as short-term investments
|
26,898
|
|
|
—
|
|
|
—
|
|
|
26,898
|
|
||||
|
Total
|
$
|
37,577
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
37,577
|
|
|
|
March 31, 2016
|
|
December 31, 2015
|
||||
|
|
(In thousands)
|
||||||
|
Raw materials
|
$
|
104
|
|
|
$
|
93
|
|
|
Work-in-process
|
1,692
|
|
|
158
|
|
||
|
Finished goods
|
176
|
|
|
221
|
|
||
|
Total inventory
|
$
|
1,972
|
|
|
$
|
472
|
|
|
|
March 31,
2016 |
|
December 31,
2015 |
||||
|
|
(In thousands)
|
||||||
|
Contract research and development
|
$
|
3,260
|
|
|
$
|
2,973
|
|
|
Consulting and professional fees
|
3,232
|
|
|
2,400
|
|
||
|
Employee compensation
|
2,544
|
|
|
2,590
|
|
||
|
Clinical trials
|
2,061
|
|
|
1,108
|
|
||
|
Other accruals
|
1,023
|
|
|
681
|
|
||
|
Total accrued liabilities
|
$
|
12,120
|
|
|
$
|
9,752
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2016
|
|
2015
|
||||
|
|
(In thousands)
|
||||||
|
Research and development
|
$
|
2,155
|
|
|
$
|
1,324
|
|
|
Selling, general and administrative
|
2,267
|
|
|
1,193
|
|
||
|
Total
|
$
|
4,422
|
|
|
$
|
2,517
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2016
|
|
2015
|
||||
|
Estimated weighted-average fair value
|
$
|
6.62
|
|
|
$
|
13.49
|
|
|
Weighted-average assumptions
|
|
|
|
||||
|
Expected volatility
|
74
|
%
|
|
70
|
%
|
||
|
Expected term, in years
|
5.7
|
|
|
6.0
|
|
||
|
Risk-free interest rate
|
1.44
|
%
|
|
1.51
|
%
|
||
|
Expected dividend yield
|
—
|
%
|
|
—
|
%
|
||
|
|
Options
Outstanding
|
|
Weighted-
Average
Exercise
Price per
Share
|
|
Remaining
Contractual Life
(In years)
|
|
Aggregate
Intrinsic
Value
(In thousands)
|
|||||
|
Balance at December 31, 2015
|
8,310,235
|
|
|
$
|
7.97
|
|
|
|
|
|
||
|
Granted
|
1,349,055
|
|
|
10.31
|
|
|
|
|
|
|||
|
Exercised
|
(329,013
|
)
|
|
4.87
|
|
|
|
|
|
|||
|
Forfeited
|
(27,929
|
)
|
|
14.51
|
|
|
|
|
|
|||
|
Balance at March 31, 2016
|
9,302,348
|
|
|
$
|
8.40
|
|
|
6.54
|
|
$
|
65,720
|
|
|
Vested and expected to vest at March 31, 2016
|
9,012,412
|
|
|
$
|
8.30
|
|
|
6.46
|
|
$
|
64,505
|
|
|
Exercisable at March 31, 2016
|
6,486,712
|
|
|
$
|
7.09
|
|
|
5.50
|
|
$
|
53,722
|
|
|
•
|
MASP-2 - OMS721
. OMS721, our lead MASP-2 antibody, is being developed for diseases in which the lectin pathway, one of the principal complement activation pathways, which is believed to contribute to significant tissue injury and pathology. One group of such diseases is thrombotic microangiopathies, or TMAs, including atypical hemolytic uremic syndrome, or aHUS, thrombotic thrombocytopenic purpura, or TTP, and hematopoietic stem-cell transplant, or HSCT, -related TMA. We recently initiated an OMS721 Phase 3 clinical program that consists of one single-arm (
i.e.
, no control arm), open-label trial in patients with newly diagnosed or ongoing aHUS and we expect enrollment will begin later this year. We are also currently conducting two Phase 2 clinical programs, one in patients with other TMAs (
i.e.
, HSCT-related TMA and TTP), as well as a second Phase 2 clinical program in patients with immunoglobulin A, or IgA, nephropathy and other complement-related renal diseases (
e.g.
, membranous nephropathy, lupus nephritis and C3 glomerulopathy) in which we recently initiated patient dosing in a Phase 2 clinical trial in corticosteroid-dependent renal diseases. In addition, in February 2016, we announced that Finnish physicians had requested access to OMS721 under a Special License, granted by the Finnish regulatory authorities, to treat a patient with aHUS who was previously treated with Soliris
®
(eculizumab) but was determined to not have an adequate response and who was continuing to display signs of active aHUS.
|
|
•
|
PDE10 - OMS824 for Huntington’s disease and Schizophrenia.
OMS824, our lead phosphodiesterase 10, or PDE10, inhibitor, is in a Phase 2 clinical program for the treatment of Huntington’s disease, in which clinical trials are currently subject to dosing limitations, and a Phase 2 clinical program for schizophrenia, in which no clinical trials are currently active. The dosing limitations in our Phase 2 clinical trial in Huntington’s may potentially be removed pending generation, submission and FDA review of additional information. We are conducting nonclinical studies to generate additional data for further discussion with the FDA regarding the dosing limitations and are currently preparing for a re-designed Phase 2 clinical trial in patients with Huntington’s disease. As we announced in October 2014, clinical trials evaluating OMS824 in schizophrenia are suspended currently at the request of the FDA. Given that there was no active schizophrenia trial at the time of program suspension, the FDA will address the OMS824 schizophrenia program when we have a related trial protocol ready for initiation.
|
|
•
|
PPARγ - OMS405
. In our peroxisome proliferator-activated receptor gamma, or PPARγ, program, Phase 2 clinical trials have been conducted by our collaborators to evaluate a PPARγ agonist, alone or in combination with other agents, for treatment of addiction to opioids and to nicotine. Our collaborators are analyzing data from these trials and expect to present relevant information in manuscripts to be published at a later date.
|
|
•
|
OMS201-Urology.
OMS201, our PharmacoSurgery product candidate for use during urological procedures, including uroendoscopic procedures, completed a Phase 1/Phase 2 clinical trial in 2010 and is not currently in active clinical trials.
|
|
•
|
PDE7 - OMS527.
In our PDE7 program, we are developing proprietary compounds to treat addiction and compulsive disorders as well as movement disorders.
|
|
•
|
Plasmin - OMS616
. In our Plasmin program, we are advancing novel antifibrinolytic agents for the control of blood loss during surgery or resulting from trauma as well as for other hyperfibrinolytic states (e.g., liver disease).
|
|
•
|
MASP-3 - OMS906
. In our MASP-3 program, OMS906, we are developing MASP-3 inhibitors for the treatment of disorders related to the alternative pathway of the complement system and currently are optimizing potent and functionally active antibodies in preparation for scale-up of one or more clinical candidates.
|
|
•
|
GPCR Platform and Programs
. We have developed a proprietary cellular redistribution assay, or CRA, which we use in a high-throughput manner to identify synthetic ligands, including antagonists, agonists and inverse agonists, that bind to and affect the function of orphan GPCRs. We are conducting
in vivo
preclinical efficacy studies and optimizing compounds for a number of targets including: GPR17, linked to myelin formation; GPR101, linked to appetite and eating disorders; GPR151, linked to neuropathic pain and cognition; GPR161, which is associated with triple negative breast cancer; GPR183, linked to osteoporosis and to Epstein-Barr virus infections and related diseases; and GPR174, which appears to be involved in the modulation of regulatory T cells, or “T-regs,” known to be important in autoimmune disease, such as multiple sclerosis, and in cancer and organ transplantation.
|
|
•
|
Antibody Platform.
Our proprietary
ex vivo
platform for the discovery of novel, high-affinity monoclonal antibodies, which was in-licensed from the University of Washington and then further developed by our scientists, utilizes a chicken B-cell lymphoma cell line. We have generated antibodies to several clinically significant targets, including highly potent antibodies against MASP-3, and our platform continues to add to our pipeline antibodies against additional important targets.
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2016
|
|
2015
|
||||
|
|
(In thousands)
|
||||||
|
Product sales, net
|
$
|
7,246
|
|
|
$
|
238
|
|
|
Small Business Innovative Research Grants (SBIR)
|
173
|
|
|
150
|
|
||
|
Total revenue
|
$
|
7,419
|
|
|
$
|
388
|
|
|
|
Chargebacks and Rebates
|
|
Distribution Fees and Product Return Allowances
|
|
Total
|
||||||
|
|
(In thousands)
|
||||||||||
|
Balance as of December 31, 2015
|
$
|
180
|
|
|
$
|
277
|
|
|
$
|
457
|
|
|
Provision related to current period sales
|
285
|
|
|
268
|
|
|
553
|
|
|||
|
Payments made/credits granted
|
(220
|
)
|
|
(189
|
)
|
|
(409
|
)
|
|||
|
Balance as of March 31, 2016
|
$
|
245
|
|
|
$
|
356
|
|
|
$
|
601
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2016
|
|
2015
|
||||
|
|
(In thousands)
|
||||||
|
Direct external expenses:
|
|
||||||
|
Clinical research and development:
|
|
|
|
||||
|
OMS721
|
$
|
5,996
|
|
|
$
|
1,233
|
|
|
OMIDRIA (OMS302)
|
1,266
|
|
|
754
|
|
||
|
OMS824
|
272
|
|
|
532
|
|
||
|
Other clinical programs
|
15
|
|
|
17
|
|
||
|
Total clinical research and development
|
7,549
|
|
|
2,536
|
|
||
|
Preclinical research and development
|
488
|
|
|
501
|
|
||
|
Total direct external expenses
|
8,037
|
|
|
3,037
|
|
||
|
|
|
|
|
||||
|
Internal, overhead and other expenses
|
5,242
|
|
|
4,957
|
|
||
|
Stock-based compensation expense
|
2,155
|
|
|
1,324
|
|
||
|
Total research and development expenses
|
$
|
15,434
|
|
|
$
|
9,318
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2016
|
|
2015
|
||||
|
|
(In thousands)
|
||||||
|
Selling, general and administrative expenses, excluding stock-based compensation expense
|
$
|
8,843
|
|
|
$
|
7,796
|
|
|
Stock-based compensation expense
|
2,267
|
|
|
1,193
|
|
||
|
Total selling, general and administrative expenses
|
$
|
11,110
|
|
|
$
|
8,989
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2016
|
|
2015
|
||||
|
|
(In thousands)
|
||||||
|
Interest expense
|
$
|
1,375
|
|
|
$
|
957
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2016
|
|
2015
|
||||
|
|
(In thousands)
|
||||||
|
Other income (expense), net
|
$
|
288
|
|
|
$
|
218
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2016
|
|
2015
|
||||
|
|
(In thousands)
|
||||||
|
Selected cash flow data
|
|
|
|
||||
|
Cash provided by (used in):
|
|
|
|
||||
|
Operating activities
|
$
|
(16,628
|
)
|
|
$
|
(17,476
|
)
|
|
Investing activities
|
14,632
|
|
|
(62,089
|
)
|
||
|
Financing activities
|
1,609
|
|
|
80,652
|
|
||
|
•
|
a lack of acceptance by physicians, patients, government and private payers and other members of the medical community;
|
|
•
|
our limited experience in marketing, selling and distributing OMIDRIA or any other product;
|
|
•
|
our limited experience managing third-party commercial manufacturing of OMIDRIA or any other product as well as our limited experience managing and maintaining a commercial sales organization;
|
|
•
|
pricing, reimbursement and coverage policies of government and private payers such as Medicare, Medicaid, the Department of Veterans Affairs, or VA, group purchasing organizations, insurance companies, health maintenance organizations and other plan administrators;
|
|
•
|
the availability, relative price and efficacy of the product as compared to alternative treatment options or branded, compounded or generic competing products;
|
|
•
|
an unknown safety risk;
|
|
•
|
the failure to enter into and maintain acceptable partnering arrangements for marketing and distribution of OMIDRIA outside of the U.S.;
|
|
•
|
changed or increased regulatory restrictions in the U.S., EU and other foreign territories; and
|
|
•
|
a lack of adequate financial or other resources.
|
|
•
|
the level and timing of commercial sales of OMIDRIA as well as our product candidates, if and when approved or commercialized;
|
|
•
|
the extent of coverage and reimbursement for OMIDRIA, including following the expiration of pass-through reimbursement effective January 1, 2018, and the amount of OMIDRIA chargebacks, rebates and product returns;
|
|
•
|
the extent of any payments received from collaboration arrangements and development funding as well as the achievement of development and clinical milestones under collaboration and license agreements that we may enter into from time to time and that may vary significantly from quarter to quarter; and
|
|
•
|
the timing, cost and level of investment in our research and development activities as well as expenditures we will or may incur to acquire or develop additional technologies, products and product candidates.
|
|
•
|
continue OMIDRIA sales and marketing;
|
|
•
|
continue research and development in our programs;
|
|
•
|
make principal and interest payments under the Oxford/EWB Loan Agreement;
|
|
•
|
initiate and conduct clinical trials for our programs and product candidates; and
|
|
•
|
commercialize and launch product candidates for which we may receive regulatory approval.
|
|
•
|
reduced protection for intellectual property rights;
|
|
•
|
unexpected changes in tariffs, trade barriers and regulatory requirements;
|
|
•
|
economic weakness, including inflation, or political instability in particular foreign economies and markets;
|
|
•
|
foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country; and
|
|
•
|
business interruptions resulting from geopolitical actions, including war and terrorism or natural disasters including earthquakes, typhoons, floods and fires.
|
|
•
|
discussions with the FDA, the EMA or other foreign authorities regarding the scope or design of our clinical trials;
|
|
•
|
delays or the inability to obtain required approvals from Institutional Review Boards, Ethics Committees or other responsible entities at clinical sites selected for participation in our clinical trials;
|
|
•
|
delays in enrolling patients into clinical trials for any reason including disease severity, trial protocol design, study eligibility criteria, patient population size (
e.g.
, for orphan diseases or for some pediatric indications), proximity and/or availability of clinical trial sites for prospective patients, availability of competing therapies and clinical trials, regional differences in diagnosis and treatment, perceived risks and benefits of the product or product candidate, physician patient referral practices or the ability to monitor patients adequately before and after treatment;
|
|
•
|
lower than anticipated retention rates of patients in clinical trials;
|
|
•
|
the need to repeat or conduct additional clinical trials as a result of inconclusive or negative results, failure to replicate positive early clinical data in subsequent clinical trials, poorly executed testing, a failure of a clinical site to adhere to the clinical protocol, an unacceptable study design or other problems;
|
|
•
|
adverse findings in clinical or nonclinical studies related to the safety of our product candidates in humans;
|
|
•
|
an insufficient supply of product candidate materials or other materials necessary to conduct our clinical trials;
|
|
•
|
the need to qualify new suppliers of product candidate materials for FDA and foreign regulatory approval;
|
|
•
|
an unfavorable inspection or review by the FDA or other regulatory authority of a clinical trial site or records of any clinical investigation;
|
|
•
|
the occurrence of unacceptable drug-related side effects or adverse events experienced by participants in our clinical trials;
|
|
•
|
the suspension by a regulatory agency of a trial put on a clinical hold; and
|
|
•
|
the amendment of clinical trial protocols to reflect changes in regulatory requirements and guidance or other reasons as well as subsequent re-examination of amendments of clinical trial protocols by Institutional Review Boards or Ethics Committees.
|
|
•
|
failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;
|
|
•
|
inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;
|
|
•
|
the failure to remove a clinical hold in a timely manner (which we cannot predict with certainty), if at all;
|
|
•
|
unforeseen safety issues or any determination that a trial presents unacceptable health risks; or
|
|
•
|
lack of adequate funding to continue the clinical trial or development program, including the incurrence of unforeseen costs due to enrollment delays, requirements to conduct additional trials and studies and increased expenses associated with the services of our contract research organizations, or CROs, and other third parties.
|
|
•
|
we may not be able to generate sufficient data to support full patent applications that protect the entire breadth of developments in one or more of our programs, including our GPCR program;
|
|
•
|
it is possible that one or more of our pending patent applications will not become an issued patent or, if issued, that the patent(s) will be sufficient to protect our technology, provide us with a basis for commercially viable products or provide us with any competitive advantages;
|
|
•
|
if our pending applications issue as patents, they may be challenged by third parties as not infringed, invalid or unenforceable under U.S. or foreign laws; or
|
|
•
|
if issued, the patents under which we hold rights may not be valid or enforceable.
|
|
Exhibit
Number
|
Description
|
|
12.1
|
Ratio of Earnings to Fixed Charges
|
|
31.1
|
Certification of Principal Executive Officer Pursuant to Rule 13-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
31.2
|
Certification of Principal Financial Officer Pursuant to Rule 13-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
32.1
|
Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
32.2
|
Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
101.INS
|
XBRL Instance Document
|
|
101.SCH
|
XBRL Taxonomy Extension Schema Document
|
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
|
OMEROS CORPORATION
|
|
|
|
|
Dated: May 10, 2016
|
/s/ Gregory A. Demopulos
|
|
|
Gregory A. Demopulos, M.D.
|
|
|
President, Chief Executive Officer and Chairman of the Board of Directors
|
|
|
|
|
Dated: May 10, 2016
|
/s/ Michael A. Jacobsen
|
|
|
Michael A. Jacobsen
|
|
|
Vice President, Finance, Chief Accounting Officer and Treasurer
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|